Fraguas-Sánchez, A.I.; Torres-Suárez, A.I.; Cohen, M.; Delie, F.; Bastida-Ruiz, D.; Yart, L.; Martin-Sabroso, C.; Fernández-Carballido, A.
PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment. Pharmaceutics 2020, 12, 439.
https://doi.org/10.3390/pharmaceutics12050439
AMA Style
Fraguas-Sánchez AI, Torres-Suárez AI, Cohen M, Delie F, Bastida-Ruiz D, Yart L, Martin-Sabroso C, Fernández-Carballido A.
PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment. Pharmaceutics. 2020; 12(5):439.
https://doi.org/10.3390/pharmaceutics12050439
Chicago/Turabian Style
Fraguas-Sánchez, Ana I., Ana I. Torres-Suárez, Marie Cohen, Florence Delie, Daniel Bastida-Ruiz, Lucile Yart, Cristina Martin-Sabroso, and Ana Fernández-Carballido.
2020. "PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment" Pharmaceutics 12, no. 5: 439.
https://doi.org/10.3390/pharmaceutics12050439
APA Style
Fraguas-Sánchez, A. I., Torres-Suárez, A. I., Cohen, M., Delie, F., Bastida-Ruiz, D., Yart, L., Martin-Sabroso, C., & Fernández-Carballido, A.
(2020). PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment. Pharmaceutics, 12(5), 439.
https://doi.org/10.3390/pharmaceutics12050439